MedPath

Treatment of Osteoarthritis of knee with Agnikarma

Phase 3
Not yet recruiting
Conditions
Osteoarthritis of knee, unspecified. Ayurveda Condition: JANUSANDHIGATAVATA,
Registration Number
CTRI/2022/02/040117
Lead Sponsor
ITRA
Brief Summary

The presenr clinical trial is an open labelled randomized control clinical trial on Janusandhigata Vata (O.A. Knee).In this study total 30 patients will be registered and divided into 2 groups with minimum 15 patients in each group. The interventional group A will receive Agnikarma by Panchadhatu Shalaka and group B will receive Agnikarma by Electrocautery. Total duration of study is 4 weeks with follow up after 8 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Patients suffering from Janusandhigata Vata (O.A. of knee joint) Patient indicated for Agnikarma as per classics (severe pain at Janusandhi).

Exclusion Criteria
  • Patients of Diabetes mellitus, R.A. (Rheumatoid Arthritis) positive, Gouty arthritis, Gross Knee Joint Effusion.
  • Other Diseases like Paralysis, Parkinson’s disease, cardiac diseases, pacemaker in situ, renal diseases and endocrine diseases, severe Anemia, and malignancy.
  • Pregnant and Lactating females.
  • Known cases of secondary O.A. due to T.B., Syphilis, AIDS, Leprosy etc.
  • Patients contraindicated for Agnikarma as per classics-Pitta Prakruti Rogi, Durbala (weak), Bheeru (afraid), Sharad and Grishma Ritu.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
relief in sign and symptomsassess after 4 weeks
Secondary Outcome Measures
NameTimeMethod
Increase quality of life style12 weeks

Trial Locations

Locations (1)

ITRA PG HOSPITAL

🇮🇳

Jamnagar, GUJARAT, India

ITRA PG HOSPITAL
🇮🇳Jamnagar, GUJARAT, India
Krishna Rathod
Principal investigator
9427300092
krishna.rathod2225@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.